Earnings call
Sun Pharmaceutical Industries Q4 FY26 earnings call: Sun Pharmaceutical Industries Limited expects some of its elevated spends in the fourth quarter of FY '26 to normalize in subsequent quarters
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company filed one other transcript for this quarter. This page reads the one with the speakers marked, then the most statements.
The company expects some of its elevated spends in the fourth quarter of FY '26 to normalize in subsequent quarters. Sales were INR1,45,598 million in the fourth quarter of FY '26, up 13.6% vis-a-vis Q4 FY '25. The company ranked number 1 and held 8.4% market share in the over INR 2,450 billion Indian pharmaceutical market as per PharmaTrac MAT March '26. The company launched UNLOXCYT and 2 new generic products in the US during the fourth quarter of FY '26. The Board has approved a final dividend of INR 5 per share for the year FY '26, in addition to an interim dividend of INR 11 per share, taking the total dividend for the year to INR 16 per share.
The numbers management gave
Results
- Sales were INR1,45,598 million in the fourth quarter of FY '26, up 13.6% vis-a-vis Q4 FY '25.
Show source
During the fourth quarter of FY '26, sales were at INR1,45,598 million, registering a growth of 13.6% vis-a-vis Q4 FY '25.
- Gross margin was 80.8% in the fourth quarter of FY '26, higher than the same period last year largely on account of better product mix.
Show source
Gross margin was at 80.8% for the quarter, higher than the same period last year, largely on account Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 of better product mix.
- EBITDA was INR 39,542 million in the fourth quarter of FY '26, an increase of 6.4% over Q4 last year.
Show source
EBITDA for the quarter was INR 39,542 million, an increase of 6.4% over Q4 last year.
- EBITDA margin was 27.1% in the fourth quarter of FY '26, versus 28.7% year-on-year and 31.9% quarter-on-quarter.
Show source
EBITDA margin came at 27.1%, lower both on year-on-year, which was 28.7% and on a quarter-on-quarter, which was 31.9%.
- Forex gain was INR 4,268 million in the fourth quarter of FY '26.
Show source
Forex gain for the quarter was INR 4,268 million.
- Reported net profit after tax was INR 27,140 million and adjusted net profit was INR 27,507 million in Q4 FY '26.
Show source
Reported net profit after tax for Q4 FY '26 was INR 27,140 million, while adjusted net profit for the quarter was INR 27,507 million.
Show 29 more statements
Results
- Earnings per share was INR 11.31 per share in the fourth quarter of FY '26.
Show source
Earnings per share for the quarter was INR 11.31 per share.
- Effective tax rate was 22.3% in the fourth quarter of FY '26, versus 19.8% in Q4 of FY '25 and 24.3% in Q3 of FY '26.
Show source
Effective tax rate for the quarter stood at 22.3% vis-à-vis 19.8% in Q4 of FY '25 and 24.3% in Q3 of FY '26.
- Sales were INR 582 Billion in full year FY '26, a growth of 11.9%.
Show source
For the full year FY '26, sales were INR 582 Billion, a growth of 11.9%.
- Gross margin was 80.2% in full year FY '26.
Show source
Gross margin was at 80.2% for the full year FY '26.
- EBITDA was INR1,77,314 million in full year FY '26, a growth of 16.1%, with an EBITDA margin of 30.3%.
Show source
EBITDA came in at INR1,77,314 million, a growth of 16.1%, with a resulting EBITDA margin of 30.3%.
- Adjusted net profit was INR 1,24,015 million in full year FY '26.
Show source
Adjusted net profit for the full year was INR 1,24,015 million.
- Innovative Medicine sales were US$ 354 million in Q4 FY '26, up 20.1%.
Show source
In Q4 FY '26, our Innovative Medicine sales were up 20.1% to reach US$ 354 million.
- Global Innovative Medicine sales were US$ 1,420 million in full year FY '26, with growth of 16.8%.
Show source
Our Global Innovative Medicine sales for the full year FY '26 were US$ 1,420 million with a growth of 16.8%.
- Global Innovative Medicine accounted for 22.2% of Sun Pharmaceutical Industries Limited’s sales in Q4 FY '26.
Show source
This business accounted for 22.2% of the share of Sun sales for the quarter.
- Global Ilumya sales were US$ 796 million in FY '26, growing 16.7% for the year, excluding in-market sales of alliance partners.
Show source
Global Ilumya sales for FY '26 were US$ 796 million, having growth of 16.7% for the year.
- India formulations sales were INR 48,359 million in Q4 FY '26, recording growth of 14.8%.
Show source
Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 Now coming to India, the sales of India formulations were INR 48,359 million for the quarter, recording a growth of 14.8%.
- India formulation sales were INR1,92,904 million in full year FY '26, recording growth of 14%.
Show source
India formulation sales for the full year were INR1,92,904 million, recording a growth of 14%.
- India sales accounted for 33.2% of Sun Pharmaceutical Industries Limited’s total consolidated sales in Q4 FY '26.
Show source
India sales accounted for 33.2% of total consolidated sales for the quarter.
- U.S. accounted for 28.8% of Sun Pharmaceutical Industries Limited’s consolidated sales in Q4 FY '26.
Show source
U.S. accounted for 28.8% of consolidated sales for the quarter.
- Innovative Medicines crossed $1 billion in the United States for the first time in FY '26.
Show source
I'm also pleased to note for the year that Innovative Medicines crossed $1 billion for the first time in the United States.
- Formulation revenues in Emerging Markets were US$ 306 million in Q4 FY '26, up 17.4% over Q4 last year, with underlying constant currency growth of 6.5%.
Show source
Our formulation revenues in Emerging Markets were US$ 306 million, up by 17.4% over Q4 last year.
- Emerging markets accounted for 19.2% of Sun Pharmaceutical Industries Limited’s total consolidated revenue in Q4 FY '26.
Show source
Emerging markets accounted for 19.2% of total consolidated revenue for Q4.
- Formulation revenues in emerging markets were US$ 1.265 billion in full financial year FY26, up 13.6%, with constant currency growth of 8.2%.
Show source
Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 For the full financial year FY26, formulation revenues in emerging markets were US$ 1.265 billion, up by 13.6% with a constant currency growth of 8.2%.
- Formulation revenues in Rest of the World were US$ 220 million in the quarter, up 10%.
Show source
Formulation revenues in Rest of the World for the quarter were US$ 220 million, up 10%.
- ROW sales were US$ 969 million in full year FY26, up 14.4%.
Show source
For the full year FY26, ROW sales were US$ 969 million, up 14.4%.
- Rest of the world markets accounted for approximately 13.8% of Sun Pharmaceutical Industries Limited’s consolidated revenue.
Show source
Rest of the world markets accounted for approximately 13.8% of consolidated revenue.
- Consolidated investments towards R&D were INR 9,757 million, or 6.7% of sales, in quarter 4 FY26; Innovative R&D accounted for 36.9% of total R&D spend.
Show source
Consolidated investments towards R&D for quarter 4 FY26 stands at INR 9,757 million or 6.7% of sales.
- Effective tax rate was 14.7% in Q3 FY '25.
Show source
Jayashree Satagopan: Yes.
- Ex-forex EBITDA margins were lower quarter-on-quarter due to lower milestone income, some seasonality, reduced contribution from lenalidomide in Q4 versus Q3 and higher spend in certain geographies, including US.
Show source
Ex-forex, EBITDA margins were lower quarter-on-quarter due to several factors, including lower milestone income, some seasonality, reduced contribution from lenalidomide in Q4 versus Q3 and higher spend in certain geographies, including US.
- Global Innovative Medicine business growth was driven by growth across U.S. and ex U.S. market as well as Ilumya, Odomzo, Cequa and Winlevi.
Show source
The performance of this business unit continues to be driven by growth across U.S. and ex U.S. market as well as Ilumya and other products such as Odomzo, Cequa and Winlevi.
- Innovative Medicines was an important new driver of Sun Pharmaceutical Industries Limited’s Emerging Markets growth for the year, with ILUMYA doing well in Romania, Brazil and the partner market of China, alongside continued growth in branded generics.
Show source
While branded generics has continued to grow, Innovative Medicines has been an important new driver for growth in Emerging Markets for the year, with ILUMYA doing well across several markets such as Romania, Brazil and as well as the partner market of China.
- Innovative Medicines, led by ILUMYA and Odomzo, were key drivers of Sun Pharmaceutical Industries Limited’s growth in ROW, including sales in non-alliance markets.
Show source
Innovative Medicines, led by ILUMYA and Odomzo have been the key drivers for growth in ROW, including sales in non-alliance markets.
Money and capital
- The Board has approved a final dividend of INR 5 per share for the year FY '26, in addition to an interim dividend of INR 11 per share, taking the total dividend for the year to INR 16 per share.
Show source
This is in addition to the interim dividend of INR 11 per share, taking the total dividend for the year to INR 16 per share.
- The company had net cash of $3.2 billion at the consolidated level.
Show source
Balance sheet continues to be strong with a net cash of $ 3.2 billion at the consolidated level.
What it expects ahead
What management expects
- The company expects some of its elevated spends in the fourth quarter of FY '26 to normalize in subsequent quarters.
Show source
Some of these spends were elevated for the quarter, and we should see it normalizing in the subsequent quarters.
- The company expects FY27 R&D spend to be 6% to 7% of sales.
Show source
We expect our FY27 R&D spend to be 6% to 7% of the sales for the next year.
- The company has factored expenses relating to UNLOXCYT and LEQSELVI into its plan for FY '27.
Show source
However, the expenses relating to UNLOXCYT and LEQSELVI has been factored in the plan for the year.
- The company expects high single-digit consolidated top line growth for FY27 based on its current understanding of the regulatory and macro environment.
Show source
On the guidance, we expect high single-digit consolidated top line growth for FY27 based on our current understanding of the regulatory and macro environment.
- The company is not factoring any sales of UNLOXCYT and LEQSELVI from geographies other than the US this year.
Show source
Dilip Shanghvi: I think we are not factoring any sales out of this product in any geographies other than the US this year.
- The company will guide for filing as well as approval of UNLOXCYT and LEQSELVI if there are developments in geographies other than the US.
Show source
If there is, we will guide both for filing as well as approval.
What it is building and selling
Projects and capacity
- The company has an active Phase III trial underway for LEQSELVI in adolescents.
Show source
We do have an active Phase III trial underway for LEQSELVI in adolescents, you're correct.
Demand and pricing
- The company ranked number 1 and held 8.4% market share in the over INR 2,450 billion Indian pharmaceutical market as per PharmaTrac MAT March '26.
Show source
Sun Pharma is ranked number 1 and holds 8.4% market share in over INR 2,450 billion Indian pharmaceutical market as per PharmaTrac MAT March '26.
Segments
- The company launched UNLOXCYT and 2 new generic products in the US during the fourth quarter of FY '26.
Show source
As you know, we launched UNLOXCYT in the US during the fourth quarter, and we also launched 2 new generic products in the US.
- The company launched semaglutide injections under the brand names Noveltreat and Sematrinity in India, in all strengths, during Q4.
Show source
During Q4, we launched semaglutide injection under the brand name Noveltreat and Sematrinity in India across all the strengths.
- Innovative Medicines became the larger of Sun Pharmaceutical Industries Limited’s businesses in the US compared with generics, following the trajectory since ILUMYA’s launch and contributions from Cequa, Odomzo and Winlevi.
Show source
Having had a strong trajectory since the launch of ILUMYA and contributed to by products, including Cequa, Odomzo and Winlevi, Innovative Medicines is now the larger of the businesses in the US when compared to generics.
Risks, rules and outside factors
Rules and policy
- During the quarter, U.S. FDA accepted review of the BLA of Ilumya for treatment of adults with active psoriatic arthritis, with a regulatory action date set for late October '26.
Show source
During the quarter, U.S. FDA accepted the review of BLA of Ilumya for the treatment of adults with active psoriatic arthritis with regulatory action date set for late October '26.
Everything else said on the call
What management stressed
- The company is actively looking at a number of potential lifecycle management opportunities for its portfolio, including Levulan. Replaced by a later filing.
Show source
And yes, along with the rest of the portfolio, we -- Levulan, we're actively looking at a number of different potential LCM opportunities.
Group structure
- Organon’s established brand business, which is not growing and accounts for 50% of Organon, complements Sun Pharmaceutical Industries Limited’s branded generic business; biosimilar is a new addition.
Show source
But I think there are 4 parts of business where biosimilar is a new addition and the established brand, which is not growing, but which is a 50% of Organon complements with the branded generic business, what we have.
- Organon’s women's health business will add to Sun Pharmaceutical Industries Limited’s innovative business, with the combined Innovative business contribution reaching 26% to 27%.
Show source
And the women's health is an innovative business, which will also add to our innovative business and our Innovative business contribution, both combined together goes to 26% to 27%.
- Following the Organon acquisition announcement, Sun Pharmaceutical Industries Limited has set up an integration management office and initiated activities for day one preparedness; regulatory filings in various markets are in progress.
Show source
Further to our announcement of Organon acquisition, we've set up an integration management office and have initiated activities for day one preparedness.
- The company expects the Organon acquisition to be completed in Q4 FY27.
Show source
We expect the acquisition to be completed in Q4 FY27.
- The company and Organon have very negligible product overlap.
Show source
Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 So in my opinion, it's a complementary because we don't have even product overlaps, very negligible product overlap is there.
Show 1 more statement
Group structure
- Women’s health portfolio will be added on the innovative side to its existing innovative products in dermatology, ophthalmology and some part in oncology through the Organon integration.
Show source
So what gets added is a women's health on the innovative side to our existing innovative products in dermatology, ophthalmology and some part in oncology.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Kunal Dhamesha: Hi good evening and thank you for the opportunity. First question for Richard. If you could share some initial print on UNLOXCYT launch, how has been the doctor's experience with the product? And where is the product making its mark on efficacy, safety side? And a related question on that. Within the competitive landscape, do you expect one of the competitors to kind of vacate the Part B channel eventually given their new dosage form? That's the first question. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 432
Answer, richard ascroft
Thank you. Yes, the receptivity has been very positive. I think you may recall from the last call, we talked about the unique attributes of UNLOXCYT. And what makes the product unique is that it really provides balance of efficacy and tolerability. And this patient population tends to be more frail and more prone to adverse events. And if you look at the mechanism of action of UNLOXCYT, it preserves PD-L2 functioning, and that pathway is thought to be the pathway that leads to immune-mediated adverse events. So that's what we're hearing back from physicians.
Answer, richard ascroft
Not only are they seeing the efficacy that they expected, but they also are not seeing immune-mediated adverse events, which we believe is unique about the product. So physicians have been positive. We've been actively working with integrated health systems where a lot of these patients are to make sure that the product is available on their formularies. And we have made sure they're providing adequate training so their nurses know how to administer the product and patients have the best possible experience. As to your other question, you would be better off asking our competitors their strategies as it relates to Part B and Part D reimbursement.
Question
Kunal Dhamesha: Sure. Thank you for the update. Second one for Kirti, sir, on the semaglutide launch in India. I think the data agencies, which primarily track the secondary sales data, where our market share at this point in time are not in the top 3 where we are in antidiabetic, we are in top 3, right? But in terms of prescription share, how is that market panning for us? And where do you see we be in that market, let's say, from one year down the line perspective?
Answer, kirti ganorkar
Kirti Ganorkar: Sure. We launched Noveltreat on 21st March. So I would say what reflection you are seeing both in IMS or AWACS or even the prescription may not be adequate because any new product when we launch, it takes time for a complete reflection. So maybe in the next 5, 6 months, you will see the reflection, which is close to reality. Being said that, the product has been received very well by the doctor's community. And one of the differentiating point is our auto-injector as well as the pen system, which was appreciated by the doctors and patients equally well. So current reflection, what you are saying is right.
Answer, kirti ganorkar
We are, what you are saying, we are not number one player in the GLP-1 generics. But as I said, the reflection and the reality takes some time to reflect, and our endeavour is always to remain leader in the market.
Question
Kunal Dhamesha: And sir, any clarity on will we be there in the oral semaglutide market anytime soon? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 Kirti Ganorkar: Sure.
Answer, kirti ganorkar
So for oral, we have completed the clinical study. And once we get approval, we will launch the product at the earliest.
Question
Surya Patra: So sequential drop in the margin, that was my question. So, and how much of this drop is because of, let's say, Revlimid driven and hence can continue going ahead?
Answer, jayashree satagopan
Jayashree Satagopan: So the impact of Revlimid in this is relatively small.
Question
Surya Patra: Okay. And any one-off cost component that is sitting in the other expenses, ma'am? And can you quantify that, which may not be recurring?
Answer, jayashree satagopan
Jayashree Satagopan: No, there are multiple small items that have together come up to this level. That is why I was also mentioning you should see some amount of normalization as we go forward.
Question
Surya Patra: Okay. Okay. Second question is about, although we are not discussing Organon acquisition related aspects, and I'm not asking anything about that. But in what way, see, I think both are equal-sized businesses. So if you can give some sense that in what way the base business of Sun Pharma can be complemented. For example, like the cross-selling opportunity, that would be a kind of a common thing. But apart from that, what other factors or what other complementing aspects that we can see for Sun Pharma's base business because of that integration?
Answer, kirti ganorkar
Kirti Ganorkar: Sure. So I think we had done a presentation on Organon, where in the detail, Jayashree has discussed about how the business complement each other. But I think there are 4 parts of business where biosimilar is a new addition and the established brand, which is not growing, but which is a 50% of Organon complements with the branded generic business, what we have. And the women's health is an innovative business, which will also add to our innovative business and our Innovative business contribution, both combined together goes to 26% to 27%. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 So in my opinion, it's a complementary because we don't have even product overlaps, very negligible product overlap is there. And biosimilar is a new addition. So what gets added is a women's health on the innovative side to our existing innovative products in dermatology, ophthalmology and some part in oncology.
Answer, kirti ganorkar
So in my opinion, it's quite complementary business, and we are confident that both companies, when we close the transaction together, it will help us to grow further.
Question
Surya Patra: Sure, sir. Just last one question, if I may ask. So we have obviously seen a kind of a good progress in ILUMYA outside of the US, and that is what we have seen the trend also for the global sales business. So can you provide some incremental outlook for the global sales business or global innovative business outside of US? And which other products possibly can see commercial launches outside of the US from the innovative basket?
Answer, kirti ganorkar
Kirti Ganorkar: Sure. We have ILUMYA and Odomzo, these are 2 products outside the US. So if you remember a couple of quarters back, I said like ILUMYA, we launched in 35 countries. Now it has gone to 40 countries, and it is helping us to grow. At the same time, even the other non-ILUMYA portfolio is also continuing to grow, and we see that they are adding to the overall growth of the market ex-US. So overall, I would say the Innovative Medicine part of the business, either you look at US or ex US, it is helping us to grow further.
Question
Surya Patra: Sure sir. Thank you wish you all the best.
Answer, richard ascroft
Richard Ascroft: Yes. Thank you for the question. So for '26, we did see good growth for ILUMYA, but we really saw good growth across our Innovative Medicines portfolio. So it really wasn't singled out just to one brand. And certainly, if we look at this current fiscal year and the one we're coming into, we expect to see continued growth from ILUMYA. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 We still see good growth of the IL-23 market. As Kirti mentioned earlier, we also have submitted for a new extension in psoriatic arthritis.
Answer, richard ascroft
But yes, we also expect to see growth from the new brands, LEQSELVI and UNLOXCYT as well as the existing Innovative Medicines portfolio. Neha: So out of the existing portfolio, excluding LEQSELVI, let's say, Winlevi particularly, we changed our strategy there. The prescription data seems to be showing a very good traction. How much more room do you think that has with this change in strategy? Or this is just the beginning and we think there could be a much steeper improvement in Winlevi as we go through the next 2 years?
Answer, richard ascroft
Richard Ascroft: We continue to see growth based on the model that we've adopted. And we also continue to see good growth of Cequa, a product that you didn't mention, where we think that will continue for the next years as well. Neha: Okay. And last on LEQSELVI, how are you thinking about, I mean, based on your conversation with formulary partners, is market formation becoming a little more easier? How do you think we should think about this product, ramp-up of this product given what we are seeing on the competitive landscape with one of our competitors sort of slowing down on promotion, a likely new competitor coming in?
Answer, richard ascroft
Richard Ascroft: Yes. I think there are a couple of things in that question. First of all, we have continued to improve our access position. So as of April 1, we have a majority of access now in the US market. We've continued to expand our testing regimens. So that is another plus. And then I think you're probably referring to a new competitor that may launch.
Answer, richard ascroft
I think, look, any time there's competition, it's a good thing for patients to have choices. We know that there's still, even with the best products, there's still patients that don't respond. By having another competitor, we do believe that will help grow the market and that, that will not only create opportunities for patients, but it will create opportunities for us as well. Neha: Understood. That's very helpful. One other question, if I may. If I look at the emerging market business, obviously, there's currency tailwind there.
Answer, aalok shanghvi
Aalok Shanghvi: Yes. So I think we will certainly look at maximizing the potential, but we will not be able to provide any guidance. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 Neha: Understood thank you so much.
Question
Girish Bakhru: Hi thanks for taking my question. Just some commentary on biosimilar STELARA impact, I know it sits in a different channel, but discounts are very heavy, almost going to 90% and there have been significant formulary exclusion of branded STELARA. Has that changed anything for you for ILUMYA in terms of formulary positioning and general commentary on the market share that biosimilar might be taking?
Answer, richard ascroft
Richard Ascroft: We are seeing some impact of biosimilars changing formulary access, but we've not seen an impact on our business. Keep in mind that Medicare is one of the primary channels through which, through Part B that ILUMYA is reimbursed by, and that has no effect on the Part B reimbursement program.
Question
Girish Bakhru: Understood. And second one on UNLOXCYT. I know it's still early, but can you share how many accounts have you got on-boarded given this is an IV product? I'm understanding its positioning will be very different from how LEQSELVI will be marketed.
Answer, richard ascroft
Richard Ascroft: Thank you for the question. And you're right. The key focus for UNLOXCYT is continuing to work with the, not just infusion centres, but the academic centres as well as the integrated health delivery systems. We're not providing guidance on specifically what number of accounts have or haven't signed contracts, but we are seeing good uptake, particularly with cancer centres, and they are, we are seeing repeat purchases from those centres as well.
Show 17 more questions
Question
Girish Bakhru: Just a ballpark, would you be able to tell how many key priority accounts are there? I mean, and how many would you target? Because you last call, you mentioned you will only look for new patients. So, is it something that you would go only with a limited distribution? Or would you actually compare it with other peers how they are done?
Answer, richard ascroft
Richard Ascroft: No, it's not -- we don't have a limited distribution model because this practice is largely used in institutions, some in the community. So, we have wide access available to any academic or any institution for that matter that wants to use the product. No restrictions. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 Moderator Our next question comes from the line of Abdulkader Puranwala with ICICI Securities. Abdulkader Puranwala: So, my first question is with regards to your specialty products under development and specifically to MM2, so where we are now planning for a partnership. So exactly, if you could highlight which markets are we looking for this partnership? And in terms of the front end, what is the kind of field force which would be required for this particular drug with the partner or in select markets like US and Europe?
Answer, kirti ganorkar
Kirti Ganorkar: No, I think we have stated this for US market, we are looking for a partner for developing MM2 further.
Question
Abdulkader Puranwala: Okay. And sir, would it be fair to assume that the same would happen for the Type 2 diabetes drug as well once you complete the Phase II?
Answer, dilip shanghvi
Dilip Shanghvi: Yes. I think the idea is that in larger market where we will require a large field force to promote, we would look for a partner. In some of the emerging markets and in other geographies, we would look at marketing the product ourselves. Moderator The next question is from the line of Tushar Manudhane with Motilal Oswal Financial Services. Tushar Manudhane: Dilip sir, I would like to ask you on this generics business, while there is a great franchisee that has built on the Innovative Medicine portfolio and the R&D scope has been pretty strong. But somewhere the generics business has sort of struggled to grow. Just would like to understand what has been the major reason for this?
Answer, dilip shanghvi
Dilip Shanghvi: No, I think part of the question you answered yourself is that because of the compliance issue, we haven't been getting approval. And as all of you are aware, generic business is a business where pricing pressure will mean existing product will lose top line every year. So, I think as we start getting new approval, hopefully, we will start seeing some improvement. But I think the sales that you see as a growth in emerging markets also in India as well as Rest of the World also are developed by the same R&D team. So, we are seeing decent return on investment in terms of the R&D spend. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 Tushar Manudhane: So is there any thinking in terms of -- while maybe the existing sites compliance issue may be probably taking some more time or longer time.
Question
So, we sort of build new facility with the, let's say, the latest equipment so that the compliance issues are behi nd and hence, we have a renewed look at the generics business?
Answer, aalok shanghvi
Aalok Shanghvi: So, I think -- like we've shared in the past, I think we continue to work on training and upgrading the existing manpower and ensuring that we're at a minimum meeting or exceeding the requirements from a cGMP perspective. And I think the Greenfield facilit y is to address what we foresee as the future requirement to continue to be able to support the business across the world.
Question
Tushar Manudhane: So, are we in the process of setting up Greenfield for US generics specifically is what I was trying to ask?
Answer, aalok shanghvi
Aalok Shanghvi: US generics would be a part of the volume that would be manufactured, but it would not be the stand-alone trigger for the Greenfield facility.
Answer, abhishek sharma
Abhishek Sharma: Tushar, we are referring to the Madhya Pradesh plant that is coming up.
Question
Tushar Manudhane: Yes, yes. I mean just conceptually, so I'm just trying to think through that while the compliance issue has sort of impacted our business for a pretty long period of time. But I just wanted to understand that is the generics outlook promising enough that w e can look for a newer facility so that we have a compliance in place and hence, the growth prospects remain strong? Or are we sort of questioning the generics industry prospects?
Answer, dilip shanghvi
Dilip Shanghvi: No, we are not challenging -- I mean, changing our view on attractiveness of generic business. And the new facility is not only for compliance, I think it's also to ensure that we have new supply capacity as our volume continues to expand year after year. And as like what Aalok indicated, I think it's a facility being set up for supplying to major global geographies.
Question
Tushar Manudhane: Sure, sir. That's helpful. Just one more, if I may. So, this facility -- sorry for my ignorance. So, this will have what kind of doses in terms of oral solid injectables?
Answer, aalok shanghvi
Aalok Shanghvi: Yes. This is a sterile -only facility. Moderator The next question is from the line of Kunal Dhamesha with Macquarie. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 Kunal Dhamesha: One for Dilip bhai.
Question
On the R&D front, we have guided for 6% to 7% as a percentage of revenue. So, in terms of the broader split between the innovation and the generic spending, should we assume it in line with the historical track record of 40%, 60%?
Answer, dilip shanghvi
Dilip Shanghvi: So, I think you must have seen that both the last quarter overall R&D spend has grown over the rest of the year, and also the overall percentage of money spent on innovative R&D has also gone up. So, my expectation is that this will continue to be this. I can't specifically give you a response as to whether it will be 40%, 60%, 45%, what you call 55% or maybe different. But as more and more products get into our development pipeline, the innovative R&D spend will go up.
Question
Kunal Dhamesha: So, let me put it this way, like the percentage spent on or the money spent on innovation divided by innovation revenue that proportion for the last couple of years has gone down, right? So, is there a strategic emphasis that we want to reinvest certain broad range of percentage of revenue from the innovation business into innovation, especially in our existing molecule? Or is it more of a function of whatever trial comes in or there is a broader strategic emphasis that at least x percentage we want to invest?
Answer, dilip shanghvi
Dilip Shanghvi: No, I think, we have an active life cycle management approach for all our innovative products. And sometimes the investment versus return looking at the residual IP rights on the product make it difficult for us to commit large sums because we would have relatively low residual IP period. So, I think the idea for us is to accelerate our capability to identify and initiate the life cycle management programs faster.
Question
Kunal Dhamesha: Sure. And one for Jayashree, ma'am. On the intangible asset increase, I think is it related to the commercialization of the two molecules and hence, has it increased? So how to think about that? Or is there some milestone payment which we have capitalized?
Answer, jayashree satagopan
Jayashree Satagopan: You're right. This is relating to the commercialization of these two molecules.
Question
Kunal Dhamesha: So, let's say, work in progress intangible has been classified as the intangible asset? Is it the correct way to understand?
Answer, abhishek sharma
Abhishek Sharma: For LEQSELVI, yes, and for Checkpoint, yes, it was never under CWIP. Moderator The next question is from the line of Vishal Manchanda with Systematix Group. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 Vishal Manchanda: In FY27, I think we don't have a large specialty launch.
Question
So, is it fair to expect that the operating cost growth will moderate in the current year, and we should see operating leverage kicking in?
Answer, richard ascroft
Richard Ascroft: I think the -- it's important to sustain launches as well. So, you should expect that we will continue to be investin g in LEQSELVI and UNLOXCYT going forward. It will become part of our base spend. And that's already been factored into our guidance.
Question
Vishal Manchanda: Any timelines with respect to how should we see these launches happening in Europe and other markets, UNLOXCYT and LEQSELVI?
Answer, dilip shanghvi
Dilip Shanghvi: I think we are not factoring any sales out of this product in any geographies other than the US this year. If there is, we will guide both for filing as well as approval.
Question
Vishal Manchanda: So, is it these markets are not large enough? Or will we need to do additional trials here and we are probably thinking about it?
Answer, dilip shanghvi
Dilip Shanghvi: No, I think sometimes you have to -- the filing itself requires a certain time because you have to recognize that these are products that we license from somebody. So, if the -- and they only wanted to file the product in the US. So it requires adopting the existing data to recalibrate for different geographies. So, it takes a certain amount of time. We are not taking a view that it's -- the other geographies are not attractive. Because if you see competing products, they do quite well in other geographies also.
Question
Vishal Manchanda: Understood. And just on the generic business, do we expect any re -inspections maybe at Baska or Halol this year?
Answer, aalok shanghvi
Aalok Shanghvi: So, I think the sites operate from a 24/7 audit readiness. I think we would not be able to predict as to when the FDA would audit our sites.
Question
Vishal Manchanda: Okay. And I have one more question on Winlevi, the innovator company has done a trial on androgenic alopecia, and they have got positive data. Does -- would Sun have any right of first refusal here?
Answer, kirti ganorkar
Kirti Ganorkar: Since this is a pipeline question, we won't be able to answer it. Moderator The next question is from the line of Shashank Krishnakumar from Emkay Global. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 S. Krishnakumar: Just wanted to check on LEQSELVI.
Answer, richard ascroft
Richard Ascroft: Yes. We do have an active Phase III trial underway for LEQSELVI in adolescents, you're correct. And yes, along with the rest of the portfolio, we -- Levulan, we're actively looking at a number of different potential LCM opportunities.
Question
Saion Mukherjee: In fiscal '27?
Answer, richard ascroft
Richard Ascroft: Marginal impact. Moderator Our next question is from the line of Damayanti Kerai with HSBC. Damayanti Kerai: My question is regarding your EBITDA margin trajectory. So, you mentioned you will continue to invest in the new launches of LEQSELVI and UNLOXCYT in the US, etcetera, and you have given R&D guidance. So, moving from, say, fourth quarter base, how should we assume EBITDA margins to move ahead directionally?
Answer, jayashree satagopan
Jayashree Satagopan: So, as you know, we do not guide on the margins. However, the expenses relating to UNLOXCYT and LEQSELVI has been factored in the plan for the year.
Question
Damayanti Kerai: Sure. And can you indicate your effective tax rate for next year and beyond?
Answer, jayashree satagopan
Jayashree Satagopan: Yes. We expect the effective tax rate to be in the range of 25%. Moderator Ladies and gentlemen, we have no further questions. I would now like to hand the conference over to the management for closing comments. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q4 FY26 Earnings Call Transcript 06:30 pm May 22, 2026 Abhishek Sharma: Thank you, ladies and gentlemen.
Questions about this call
- When was the Sun Pharmaceutical Industries Q4 FY26 earnings call transcript filed?
- Sun Pharmaceutical Industries filed the transcript with the exchange on 29 May 2026. This page is built from that transcript.
- What does this page list?
- 54 statements from the transcript across 9 topics, 39 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 27 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.